ライフサイエンスコーパス: immunosuppressed

1 ressed, immune reconstituted, never severely immunosuppressed).

2 sh also developed in the monkey that was not immunosuppressed.

3 genic, particularly when infected people are immunosuppressed.

4 illness and opportunistic infection for the immunosuppressed.

5 s is required for the duration of time while immunosuppressed.

6 kidney transplant recipients who are already immunosuppressed.

7 morbidity and mortality in patients who are immunosuppressed.

8 in individuals who are over the age of 50 or immunosuppressed.

9 lignancies, many individuals with cancer are immunosuppressed.

10 sease, and life-threatening pneumonia in the immunosuppressed.

11 focus on these features in patients who are immunosuppressed.

12 with SVV, and 5 months later, 4 monkeys were immunosuppressed; 1 monkey was not immunosuppressed but

13 Most patients with 10 or more CSCCs were immunosuppressed (15 of 19 [78.9%]).

14 ant recipients (average age = 54 years, time immunosuppressed = 8.9 years), 135 (27%) had basal cell

15 fter variable lengths of infection in 25% of immunosuppressed acquired immune deficiency syndrome pat

16 ng children and more extensive infections in immunosuppressed adults, has constrained our understandi

17 s in young children and severe infections in immunosuppressed adults.

18 nary artery followed by reperfusion and were immunosuppressed after MI with cyclosporine and methylpr

19 Four patients were immunosuppressed after solid organ transplant and all we

20 aths occurred among patients who were obese, immunosuppressed, aged >65 years, or received oseltamivi

21 Cancer patients are frequently immunosuppressed and at risk for a wide range of opportu

22 n-years and 0.43 per 100 person-years in the immunosuppressed and corticosteroid only groups, respect

23 re human skin cancer that most often affects immunosuppressed and elderly persons.

24 C gattii, with infections occurring in both immunosuppressed and immunocompetent individuals.

25 eactivation of HHV-6A is frequent within the immunosuppressed and immunocompromised populations and r

26 combination oral antiviral regimens in other immunosuppressed and interferon refractory HCV patients.

27 cal remission, recipients may continue to be immunosuppressed and may have critically important, spec

28 atheter-related infections, especially among immunosuppressed and neutropenic patients, as well as a

29 ay be lower than previously reported both in immunosuppressed and nonimmunosuppressed patients.

30 virus-negative, often transplant recipients, immunosuppressed and on multiple medications.

31 nto adenosine, endorses the generation of an immunosuppressed and pro-angiogenic niche within the tum

32 his risk, particularly in young children and immunosuppressed and/or critically ill patients, who may

33 Injected mice were not immunosuppressed, and all survived to adulthood.

34 nly are infected with hepatitis viruses, are immunosuppressed, and have other potential hepatocellula

35 BV is more prevalent in women who are immunosuppressed, and several risk factors for the devel

36 Using xenogeneic (human) cells in immunosuppressed animals with acute ischemic heart disea

37 ing into the central nervous system (CNS) in immunosuppressed animals.

38 safety of TSO therapy in immunocompetent and immunosuppressed animals.

39 he same TSO treatment exacerbates colitis in immunosuppressed animals.

40 In this immunosuppressed background, cellular defenses provide a

41 ich these antigens are released is typically immunosuppressed, blunting the ability to initiate immun

42 rus (BKV), which can cause severe disease in immunosuppressed bone marrow and renal transplant patien

43 keys were immunosuppressed; 1 monkey was not immunosuppressed but was subjected to the stress of tran

44 nd such infections may be more severe in the immunosuppressed), but there is only anecdotal evidence

45 Dogs were initially immunosuppressed, but subsequent drug discontinuation al

46 We also tested mice severely immunosuppressed by cyclophosphamide-cortisone acetate t

47 We examined whether AM are immunosuppressed by LT.

48 ity, and potent immune adjuvant responses in immunosuppressed cancer patients.

49 Immunosuppressed cases were further subcategorized into

50 ered from a case of fatal encephalitis in an immunosuppressed child.

51 fied a related virus in the stool of another immunosuppressed child.

52 dies of the varicella vaccine in healthy and immunosuppressed children and studies of HZ vaccine in h

53 tic tool for immunoreconstitution of heavily immunosuppressed CLL patients and, in combination with b

54 may not manifest worsened survival after the immunosuppressed condition associated with severe sepsis

55 Under immunosuppressed conditions, preexisting NAb did signifi

56 associated with several human diseases under immunosuppressed conditions.

57 ion, reactivation of latent infections in an immunosuppressed context, or possible de-novo infection

58 previously reported incidence of PCP in all immunosuppressed dermatologic patients (0.1% vs 1.3%; ch

59 r risk of PCP than the general population of immunosuppressed dermatology patients.

60 eptide, and near normal glucose tolerance in immunosuppressed diabetic NOD mice transplanted intraper

61 of VPCs, a critical stenosis was created in immunosuppressed dogs, and tagged human VPCs were inject

62 soon after initial treatment; if women were immunosuppressed (eg, if they were HIV-positive); or if

63 Recipients were immunosuppressed either with cyclosporine A (CsA, 1.5 mg

64 Allografts were immunosuppressed either with cyclosporine or with cyclos

65 e hematopoietic cell transplants are usually immunosuppressed for extended periods, and infection wit

66 Treatment of T cells from immunosuppressed glioblastoma patients with miR-124 indu

67 the corticosteroid treatment-only group, the immunosuppressed group was at an increased risk of any m

68 In the immunosuppressed group, the most common malignancies wer

69 Immunosuppressed hamsters infected with SNV have a mean

70 rst report that details vismodegib use in an immunosuppressed heart transplant patient receiving cycl

71 esistance in intensive care units, expanding immunosuppressed host populations, and public health cri

72 lted from incomplete viral suppression in an immunosuppressed host with a high viral load.

73 TSPyV) occur during primary infection of the immunosuppressed host.

74 In immunosuppressed hosts with a high organism burden, orga

75 Most cases occur in immunosuppressed hosts, including patients with HIV/AIDS

76 Here, in immunosuppressed hosts, we uncover rare naturally arisin

77 ortunistic infection, especially in severely immunosuppressed hosts.

78 n of the JC virus, which generally occurs in immunosuppressed hosts.

79 anting further analysis of virus subtypes in immunosuppressed hosts.

80 K variants arising in immunocompetent versus immunosuppressed hosts; and 2) by investigating the effe

81 ymphoma (PCNSL) risk is greatly increased in immunosuppressed human immunodeficiency virus-infected p

82 stic pathogens for birds, cattle, swine, and immunosuppressed humans.

83 and nadir CD4+ T-lymphocyte counts (severely immunosuppressed, immune reconstituted, never severely i

84 adjectives such as immune, immunocompetent, immunosuppressed, immunocompromised, or immunologically

85 All patients were immunosuppressed in 18 of 24 (75%) reports with availabl

86 ble morbidity and mortality, particularly in immunosuppressed individuals ('carcinomatous catastrophy

87 y reactivation of JC polyomavirus (JCPyV) in immunosuppressed individuals and lytic infection by neur

88 ocytes and astrocytes in the white matter of immunosuppressed individuals and was almost always fatal

89 However, infection in immunocompromised or immunosuppressed individuals can result in malignant B c

90 underway to determine whether populations of immunosuppressed individuals might ultimately benefit fr

91 ion of illness associated with infections in immunosuppressed individuals put close human immunodefic

92 It has a higher incidence in immunosuppressed individuals such as organ transplant re

93 in cancer that typically affects elderly and immunosuppressed individuals, a feature suggestive of an

94 ) infection is a major cause of morbidity in immunosuppressed individuals, and congenital CMV infecti

95 es significant urinary tract pathogenesis in immunosuppressed individuals, including kidney and bone

96 AdV) infections are an increasing threat for immunosuppressed individuals, particularly those who hav

97 ers, typically of B cell origin, observed in immunosuppressed individuals, such as posttransplant or

98 In immunosuppressed individuals, VE against zoster was 0.37

99 clinical outcomes are typically observed in immunosuppressed individuals, with the most extreme case

100 to an increase in the world's population of immunosuppressed individuals.

101 matic but can lead to severe consequences in immunosuppressed individuals.

102 n and effector functions in hospitalized and immunosuppressed individuals.

103 Pneumonia is commonly diagnosed in immunosuppressed individuals.

104 are particularly numerous and aggressive in immunosuppressed individuals.

105 ulmonary sources, presenting as pneumonia in immunosuppressed individuals.

106 ainst chronic gamma-herpesvirus infection in immunosuppressed individuals.

107 idity and mortality in immunocompromised and immunosuppressed individuals.

108 is pneumonia (PCP) is a common problem among immunosuppressed individuals.

109 fections occur in immunocompetent as well as immunosuppressed individuals.

110 cause severe diseases, including cancers in immunosuppressed individuals.

111 which is a major opportunistic infection in immunosuppressed individuals.

112 lammatory diseases and cancer, especially in immunosuppressed individuals.

113 sive multifocal leukoencephalopathy (PML) in immunosuppressed individuals.

114 l leukoencephalopathy (PML) in the brains of immunosuppressed individuals.

115 associated with novel pathogenicity in some immunosuppressed individuals.

116 We tested whether the motility of hCSCs in immunosuppressed infarcted animals is controlled by the

117 Atrioventricular blocked dogs were immunosuppressed, instrumented with VVI pacemakers, and

118 of nonimmunosuppressed (non-IS) BALB/c mice, immunosuppressed (IS) BALB/c mice, TNFR1(-/-) C57BL/6 mi

119 nced pulmonary M1 macrophage polarization in immunosuppressed (IS) hosts, but an M2 predominant respo

120 Immunosuppressed (IS) iNOS(-/-) mice or C57BL/6 (wild-ty

121 studying virus replication and apoptosis in immunosuppressed (IS) TNF-alpha(-/-) mice.

122 that naive mice (i.e., not pharmacologically immunosuppressed) lacking the beta-glucan receptor Decti

123 owing to treatment-limiting toxic effects in immunosuppressed liver-transplant recipients.

124 0 neuronal infection occurs spontaneously in immunosuppressed macaques, we analyzed archival brain sp

125 pontaneous SV40 neuronal infection occurs in immunosuppressed macaques, which parallels JC virus-neur

126 Immunosuppressed male Sprague-Dawley rats were exposed t

127 is to understand in vivo efficacy within the immunosuppressed malignant ascites tissue microenvironme

128 n decisions for a pregnant woman, 73% for an immunosuppressed man, and 49% for an 8-month-old infant.

129 rude hyphal extracts protects corticosteroid-immunosuppressed mice against invasive aspergillosis.

130 s protein Asp f3 protected cortisone acetate-immunosuppressed mice from experimentally induced pulmon

131 evels of ID4 produced enlarged xenografts in immunosuppressed mice that were better vascularized than

132 valuated by treatment of BT474 xenografts in immunosuppressed mice with trastuzumab.

133 oridium parvum were generated by coinfecting immunosuppressed mice with two genetically distinct isol

134 htly, but significantly reduced mortality in immunosuppressed mice, but was unable to reduce hypoxia

135 inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the i

136 ce, and the parasites did not recur in these immunosuppressed mice.

137 al, syngeneic mice but grew progressively in immunosuppressed mice.

138 effect leading to lethality in the severely immunosuppressed mice.

139 d iron acquisition in vitro and virulence in immunosuppressed mice.

140 g protein, contributes to the creation of an immunosuppressed microenvironment at sites of tumor grow

141 de for NRAS+ melanoma suggests it has a more immunosuppressed microenvironment, which may affect its

142 growth and to maintaining a pro-tumorigenic, immunosuppressed microenvironment.

143 cessfully inoculated in the parietal lobe of immunosuppressed, mixed-breed hound dogs.

144 mellonella model and also in a persistently immunosuppressed murine model of invasive aspergillosis

145 apid appearance of de novo alloantibodies in immunosuppressed nonsensitized recipients and absence of

146 wth delay in a syngeneic model (C3H) but not immunosuppressed (Nu/Nu) squamous cell carcinoma tumor-b

147 ood pathogen that may cause acute disease in immunosuppressed or splenectomized dogs.

148 procedures and HTLV-1 disease association in immunosuppressed organ recipients were analyzed.

149 umenting the use and safety of vismodegib in immunosuppressed organ transplant patients.

150 With a growing immunosuppressed organ transplant population at high ris

151 nts with acute HEV infection, 18 HEV-exposed immunosuppressed organ-transplant recipients (8 with chr

152 ere exposed to P. jiroveci by cohousing with immunosuppressed, P. jiroveci-colonized macaques in two

153 roach to survey the viral population from an immunosuppressed patient infected with H1N1/2009 influen

154 The increase in immunosuppressed patient populations has correlated with

155 s of survival, even in the most persistently immunosuppressed patient receiving chemotherapy and/or o

156 trapping was performed on the farm where the immunosuppressed patient was employed.

157 The approach to the immunosuppressed patient with progressive neurologic dec

158 roteins of both drugs during treatment of an immunosuppressed patient with relapsing babesiosis.

159 and represents a serious health risk for the immunosuppressed patient.

160 nary tract infections (UTIs) are frequent in immunosuppressed patients after kidney transplantation a

161 It can be reactivated, however, in immunosuppressed patients and cause severe diseases, inc

162 emonstration of the immune control of CMV in immunosuppressed patients and emphasize the effectivenes

163 betaherpesvirus, can cause severe disease in immunosuppressed patients and following congenital infec

164 be challenging because of its prevalence in immunosuppressed patients and its unique vascular and in

165 Immunosuppressed patients are at risk for developing Eps

166 Immunosuppressed patients at high risk for invasive fung

167 s rarely caused acute morbidity, but in some immunosuppressed patients became persistent.

168 ent (QI) strategy to increase the numbers of immunosuppressed patients being kept up-to-date with pne

169 The reduced efficacy of PDT in immunosuppressed patients demonstrates the importance of

170 Immunosuppressed patients had an odds ratio of 1.94 of h

171 Immunosuppressed patients had significantly higher JCV D

172 major cause of life-threatening pneumonia in immunosuppressed patients including transplant recipient

173 Recently, drug resistance was reported in immunosuppressed patients infected with the 2009 pandemi

174 BKV reactivation in immunosuppressed patients or renal transplant patients i

175 ssay is extremely useful in detecting overly immunosuppressed patients vulnerable to infections.

176 Immunosuppressed patients were treated with antimetaboli

177 h may have important implications for use in immunosuppressed patients with cancer.

178 ith antigen-specific T cells has efficacy in immunosuppressed patients with Epstein-Barr virus-associ

179 treatment occurred predominantly in severely immunosuppressed patients with heavy prior micafungin ex

180 neurovirulence and in cerebrospinal fluid of immunosuppressed patients with multiple sclerosis, those

181 in a dramatic increase in the population of immunosuppressed patients with opportunistic, life-threa

182 Immunosuppressed patients with solid organ transplants h

183 he intervention has come to be known, as are immunosuppressed patients with the human immunodeficienc

184 ins or other organs of healthy people and in immunosuppressed patients without PML has been a matter

185 a HPVs have been linked to carcinogenesis in immunosuppressed patients, and high-risk cutaneous HPV8

186 tes to the development of B cell lymphoma in immunosuppressed patients, and may exacerbate flares of

187 a major cause of morbidity and mortality in immunosuppressed patients, and optimal diagnostic criter

188 clinical model for B cell lymphomagenesis in immunosuppressed patients, and validate a new therapeuti

189 Renal transplant recipients (RTRs), as all immunosuppressed patients, are at increased risk of reac

190 ty against invading pathogens, especially in immunosuppressed patients, but they also mediate graft l

191 neumocystis remains an important pathogen of immunosuppressed patients, causing a potentially life-th

192 , which causes life-threatening pneumonia in immunosuppressed patients, contains a multicopy gene fam

193 raise the diagnosis of HHV6 encephalitis in immunosuppressed patients, especially when hyperintense

194 antibiotics especially for the treatment of immunosuppressed patients, for those undergoing chemothe

195 In immunosuppressed patients, HCMV can remain relatively st

196 With an expanding at-risk population of immunosuppressed patients, increased use of invasive med

197 development of cancer is a major problem in immunosuppressed patients, particularly after solid orga

198 , which causes life-threatening pneumonia in immunosuppressed patients, remains poorly defined.

199 very useful for studying clusters of PCP in immunosuppressed patients, to determine whether there is

200 ry, and central nervous system infections in immunosuppressed patients, was identified as the cause o

201 al to prevent post-transplantation cancer in immunosuppressed patients.

202 aks and treat chronic norovirus infection in immunosuppressed patients.

203 olling active WNV infection, particularly in immunosuppressed patients.

204 ines suggest surveillance for HBV markers in immunosuppressed patients.

205 ght may contribute to skin carcinogenesis in immunosuppressed patients.

206 d as a possible cause of severe pneumonia in immunosuppressed patients.

207 ratory fungus that causes pneumonia (PcP) in immunosuppressed patients.

208 onsiderations in antifungal immunotherapy in immunosuppressed patients.

209 ich parallels JC virus-neuronal infection in immunosuppressed patients.

210 nt infection and can cause severe disease in immunosuppressed patients.

211 al evidence of disease affecting >1 organ in immunosuppressed patients.

212 eptotrichia infections have been reported in immunosuppressed patients.

213 is required with regard to TSO treatment in immunosuppressed patients.

214 course of MGUS or risk profile in long-term immunosuppressed patients.

215 s from immunocompetent patients and 59% from immunosuppressed patients.

216 l skin samples from both immunocompetent and immunosuppressed patients.

217 or the prevention and treatment of cancer in immunosuppressed patients.

218 of sunlight-related skin cancer in long-term immunosuppressed patients.

219 rr virus (EBV), and adenovirus infections in immunosuppressed patients.

220 -organ and disseminated diseases in severely immunosuppressed patients.

221 Low-level responses were detectable in immunosuppressed patients.

222 notype 3, which causes chronic infections in immunosuppressed patients.

223 NA response occurs during CMV replication in immunosuppressed patients.

224 osttransplant lymphoproliferative disease in immunosuppressed patients.

225 ) causes multicentric Castleman's disease in immunosuppressed patients.

226 hat low-virulence strains can cause NSSTI in immunosuppressed patients.

227 mportant cause of morbidity and mortality in immunosuppressed patients.

228 ll neurons and cortical pyramidal neurons in immunosuppressed people.

229 onomy, and the growing number of chronically immunosuppressed people.

230 xt, or possible de-novo infection during the immunosuppressed peritransplant period.

231 associated with adverse clinical outcomes in immunosuppressed persons, but the incidence and associat

232 hiolitis and a major pathogen in elderly and immunosuppressed persons.

233 oposed for evaluating the live HZ vaccine in immunosuppressed persons.

234 directly; however, they may locally activate immunosuppressed phagocytes that elicit the antifungal e

235 ell-specific signaling events underlying the immunosuppressed phenotype in sepsis.

236 overy cohort) identifies individuals with an immunosuppressed phenotype that included features of end

237 is intranasally instilled into dexamethasone-immunosuppressed, Pneumocystis-infected rats or L3T4 cel

238 drug toxicity, resistance, and an increasing immunosuppressed population warrant continued research i

239 infections in patients with cancer-a large, immunosuppressed population.

240 e treatment of Pneumocystis pneumonia in the immunosuppressed population.

241 ommon opportunistic infection in the diverse immunosuppressed population.

242 immunosuppressed populations, review article, editorial,

243 major cause of birth defects and disease in immunosuppressed populations.

244 as a serious cause of disease in elderly and immunosuppressed populations.

245 esvirus infection leads to severe disease in immunosuppressed populations.

246 lus fumigatus is a leading cause of death in immunosuppressed populations.

247 ocompetent rabbits than in pharmacologically immunosuppressed rabbits (treated with weekly injections

248 The protective effect of TSO was lost in immunosuppressed rabbits, where TSO exacerbated colitis.

249 rcted myocardium of immunodeficient mice and immunosuppressed rats, hCSCs generate a chimeric heart,

250 njected after acute myocardial infarction in immunosuppressed rats.

251 ation, and most often develop de novo in the immunosuppressed recipient or as recurrent malignancy af

252 ential and likelihood of transmission to the immunosuppressed recipient.

253 to reactivate after transplantation into an immunosuppressed recipient.

254 , adoptive transfer of Skn-immune T cells to immunosuppressed recipients elicits skin lesions in area

255 er of anti-Asp f3 antibodies did not protect immunosuppressed recipients from aspergillosis.

256 but no functional differences compared with immunosuppressed recipients.

257 longer and were more easily tolerized by non-immunosuppressed recipients.

258 tected (occult) cancer from organ donor into immunosuppressed recipients.

259 ld sustained allogeneic islet engraftment in immunosuppressed recipients.

260 te chronic rejection, whereas conventionally immunosuppressed renal transplant patients homozygous fo

261 During the given time, 230 immunosuppressed renal transplanted men fathered 350 chi

262 nfected six different immunodeficient and/or immunosuppressed rodent models and have demonstrated per

263 lumbar spinal ventral horn in presymptomatic immunosuppressed SOD1(G93A) rats and to assess the prese

264 shifts in metabolic polarity during the late immunosuppressed stage of human sepsis blood leukocytes

265 or patients on hemodialysis because of their immunosuppressed state and in kidney transplant patients

266 This post-traumatic immunosuppressed state has been attributed to over-expre

267 reases in GCF as a result of CsA usage or an immunosuppressed state irrespective of the severity of i

268 this process is accelerated, resulting in an immunosuppressed state that diminishes the ability of th

269 been proposed that LCMV infection induces an immunosuppressed state within the host, our data show th

270 sive inflammation temporally aligned with an immunosuppressed state, defining a complex clinical scen

271 ce, gammaherpesvirus 68 infection induces an immunosuppressed state, reminiscent of compensatory anti

272 iciency virus (HIV), malnutrition, and other immunosuppressed states.

273 or hyperinflammation by acquiring an M2-like immunosuppressed status that increases the risk of secon

274 ely 35x10(6)) versus vehicle in cyclosporine-immunosuppressed swine with a chronic left anterior desc

275 Thus, the immunosuppressed Syrian hamster is a powerful model to e

276 5 Ad (Ad5) causes severe systemic disease in immunosuppressed Syrian hamsters that is similar to that

277 GxxxG analog both associated with the CP and immunosuppressed T-cells, the AxxxG WT but not the GxxxG

278 elative to control tanks, atrazine tanks had immunosuppressed tadpoles, had significantly more attach

279 g active therapy or who are otherwise highly immunosuppressed, there is a wider spectrum of etiologie

280 uced (F-LR) platelets occurs in about 18% of immunosuppressed thrombocytopenic hematology/oncology pa

281 gan transplant recipients, who are medically immunosuppressed to prevent graft rejection, have increa

282 ains disproportionately less satisfactory in immunosuppressed transplant and oncology patients.

283 ontrolled by T cell-mediated immunity and in immunosuppressed transplant patients it is associated wi

284 V) remains a major cause of viral disease in immunosuppressed transplant patients.

285 In contrast, in immunosuppressed transplant recipients and late-stage AI

286 ing the NK and/or T cell systems, as well as immunosuppressed transplant recipients, handle EBV infec

287 to infection, an important consideration for immunosuppressed transplant recipients.

288 Immunosuppressed transplanted patients and an immunocomp

289 chemokine receptor CCR4, thus generating an immunosuppressed tumor environment.

290 In nonneutropenic mice immunosuppressed with corticosteroids, A. fumigatus stim

291 attenuated virulence in nonneutropenic mice immunosuppressed with corticosteroids, but had normal vi

292 Non-neutropenic mice that were immunosuppressed with cortisone acetate and infected wit

293 Delta145 or parental virus into guinea pigs immunosuppressed with cyclophosphamide.

294 Half of the hamsters in these groups were immunosuppressed with cyclophosphamide.

295 six models evaluated, nude rats and gerbils immunosuppressed with dexamethasone excreted the highest

296 Nonsurvivors were immunosuppressed with leukopenia and markedly reduced tu

297 th a history of orthotopic heart transplant, immunosuppressed with low-dose cyclosporine, who present

298 For immunosuppressed women (CD4 cell count, <250 cells/muL),

299 Immunosuppressed Yorkshire pigs were assigned to 1 of 3

300 re delivered by intramyocardial injection to immunosuppressed Yorkshire swine (n = 29) 2 weeks after